Show simple item record

dc.contributor.authorNikolaides, C.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorBafaloukos, Dimitriosen
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorRazi, E. D.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorPavlidis, Nicholasen
dc.creatorNikolaides, C.en
dc.creatorDimopoulos, M. A.en
dc.creatorSamantas, E.en
dc.creatorBafaloukos, Dimitriosen
dc.creatorKalofonos, H. P.en
dc.creatorFountzilas, Georgeen
dc.creatorRazi, E. D.en
dc.creatorKosmidis, Paraskevas A.en
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:54:07Z
dc.date.available2018-06-22T09:54:07Z
dc.date.issued2000
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42196
dc.description.abstractBackground: Gemcitabine and vinorelbine have shown activity in breast cancer. A phase II trial was initiated in order to evaluate the response rate (RR) and time to progression (TTP) of the combination of the two drugs in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy. Patients and methods: Thirty-one patients were treated with the combination of gemcitabine 1000 mg/m2 days 1 + 8 and vinorelbine 30 mg/m2 days 1 + 8. The cycles were repeated every three weeks. Results: Of 27 evaluable patients 1 (4%, 95% confidence interval (95% CI): 0.1%-19%) achieved complete remission (CR), five (18%; 95% CI: 6%-38%) partial remission (PR), eleven (40%; 95% CI: 22%-61%) stable disease and ten patients progressed. The median duration of response was six months (range 4-10+) and the median duration of disease stabilization was five months (range 2-22+). With a median follow-up of 16 months (range 0.4-22+) the median TTP was 3.5 months (range 0.4-22+) and the median survival was 9.5 months (range 0.4-22+). Grade 3-4 toxicities were granulocytopenia 15 patients (48%), rash 3 patients (10%), neuropathy 1 patient (3%) and thrombocytopenia 1 patient (3%). In conclusion the combination of gemcitabine/vinorelbine in the doses administered in this group of patients had a response rate of 22% and needs to be further evaluated in metastatic breast cancer.en
dc.language.isoengen
dc.sourceAnnals of Oncologyen
dc.subjectArticleen
dc.subjectFemaleen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast canceren
dc.subjectBreast neoplasmsen
dc.subjectMiddle ageden
dc.subjectAdvanced canceren
dc.subjectCancer combination chemotherapyen
dc.subjectCancer growthen
dc.subjectCancer survivalen
dc.subjectChemotherapyen
dc.subjectDisease progressionen
dc.subjectNeoplasmen
dc.subjectPriority journalen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectClinical articleen
dc.subjectClinical trialen
dc.subjectDrug resistanceen
dc.subjectNavelbineen
dc.subjectPhase 2 clinical trialen
dc.subjectTaxane derivativeen
dc.subjectTaxoidsen
dc.subjectThrombocytopeniaen
dc.subjectVinblastineen
dc.subjectVinorelbineen
dc.subjectTreatment outcomeen
dc.subjectNeoplasm metastasisen
dc.subjectGranulocytopeniaen
dc.subjectDeoxycytidineen
dc.subjectGemcitabineen
dc.subjectCancer regressionen
dc.subjectNeuropathyen
dc.subjectAdvanced breast canceren
dc.subjectRashen
dc.subjectBreast metastasisen
dc.subjectBridged compoundsen
dc.titleGemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Groupen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1023/A:1008361711049
dc.description.volume11
dc.description.issue7
dc.description.startingpage873
dc.description.endingpage875
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record